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Mobile phone use and incidence of brain tumour histological types,
grading or anatomical location: A populationbased ecological study
Abstract

Objective Some studies have reported increasing trends in certain brain tumours and a possible link with
mobile phone use has been suggested. We examined the incidence time trends of brain tumour in Australia for
three distinct time periods to ascertain the influence of improved diagnostic technologies and increase in
mobile phone use on the incidence of brain tumours.
Design In a population-based ecological study, we examined trends of brain tumour over the periods 19821992, 1993-2002 and 2003-2013. We further compared the observed incidence during the period of
substantial mobile phone use (2003-2013) with predicted (modelled) incidence for the same period by
applying various relative risks, latency periods and mobile phone use scenarios.
Setting National Australian incidence registration data on primary cancers of the brain diagnosed between
1982 and 2013.
Population 16 825 eligible brain cancer cases aged 20- 59 from all of Australia (10 083 males and 6742
females).
Main outcome measures Annual percentage change (APC) in brain tumour incidence based on Poisson
regression analysis.
Results The overall brain tumour rates remained stable during all three periods. There was an increase in
glioblastoma during 1993-2002 (APC 2.3, 95% CI 0.8 to 3.7) which was likely due to advances in the use of
MRI during that period. There were no increases in any brain tumour types, including glioma (-0.6, -1.4 to
0.2) and glioblastoma (0.8, -0.4 to 2.0), during the period of substantial mobile phone use from 2003 to 2013.
During that period, there was also no increase in glioma of the temporal lobe (0.5, -1.3 to 2.3), which is the
location most exposed when using a mobile phone. Predicted incidence rates were higher than the observed
rates for latency periods up to 15 years.
Conclusions In Australia, there has been no increase in any brain tumour histological type or glioma location
that can be attributed to mobile phones.
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Abstract
Objective Some studies have reported increasing
trends in certain brain tumours and a possible link with
mobile phone use has been suggested. We examined the
incidence time trends of brain tumour in Australia for three
distinct time periods to ascertain the influence of improved
diagnostic technologies and increase in mobile phone use
on the incidence of brain tumours.
Design In a population-based ecological study, we
examined trends of brain tumour over the periods 1982–
1992, 1993–2002 and 2003–2013. We further compared
the observed incidence during the period of substantial
mobile phone use (2003–2013) with predicted (modelled)
incidence for the same period by applying various relative
risks, latency periods and mobile phone use scenarios.
Setting National Australian incidence registration data on
primary cancers of the brain diagnosed between 1982 and
2013.
Population 16 825 eligible brain cancer cases aged 20–
59 from all of Australia (10 083 males and 6742 females).
Main outcome measures Annual percentage change
(APC) in brain tumour incidence based on Poisson
regression analysis.
Results The overall brain tumour rates remained
stable during all three periods. There was an increase in
glioblastoma during 1993–2002 (APC 2.3, 95% CI 0.8
to 3.7) which was likely due to advances in the use of
MRI during that period. There were no increases in any
brain tumour types, including glioma (−0.6, –1.4 to 0.2)
and glioblastoma (0.8, –0.4 to 2.0), during the period of
substantial mobile phone use from 2003 to 2013. During
that period, there was also no increase in glioma of the
temporal lobe (0.5, –1.3 to 2.3), which is the location most
exposed when using a mobile phone. Predicted incidence
rates were higher than the observed rates for latency
periods up to 15 years.
Conclusions In Australia, there has been no increase in
any brain tumour histological type or glioma location that
can be attributed to mobile phones.

Introduction
Since its introduction in the mid-80s mobile
phone use has grown rapidly worldwide.
When using a mobile phone against the

Strengths and limitations of this study
►► This study investigated incidence time trends for dif-

ferent brain tumour histological types, grading and
anatomical location over different time periods.
►► The study compared the observed brain tumour incidence rates with modelled predicted incidence rates
assuming a causal association with mobile phone
use.
►► Mobile phone subscription data and information
from surveys may not accurately represent mobile
phone use patterns in adults.

head, the brain is exposed to much higher
levels of radiofrequency (RF) radiation than
the rest of the body1 and there has been
continuing concern of a possible association
with brain cancer. Several case–control and
registry-based cohort studies have found little
evidence to support such an association.2
However a few other case–control studies,
most notably the Interphone study (2010)
and a Swedish study by Hardell et al have
reported modest to large associations with
glioma, the most common type of primary
brain tumour.3–5 These studies have generally found no association with other brain
tumour types such as meningioma. Based on
these results, the International Agency for
Research on Cancer (IARC) has classified RF
as ‘possibly carcinogenic to humans’.6
From a public health perspective, given that
the great majority of the population regularly uses mobile phones, even a relatively
small excess risk would result in a significant
number of additional brain tumour cases. In
time, such an increase would be observable in
cancer surveillance data sources.7 The World
Health Organization (WHO) has previously
identified as a high research priority the
monitoring of brain tumour incidence trends
through well-established population-based
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Methods
Collection of incidence data
Incidence data on primary cancers of the brain and
central nervous system diagnosed between 1982 and
2013 inclusive (the latest available) were obtained from
the Australian Institute of Health and Welfare (AIHW).
Reporting of incident invasive cancer is mandatory in all
Australian states and territories and the AIHW has been
collecting and reporting national data on brain cancer
incidence since 1982. The data included information
on primary anatomical site (International Classification
of Diseases Version 10, ICD-10 topography codes, C70–
C72), histology, diagnosis year and diagnosis age (in
5 year groups: 0–4, 5–9 … 80–84, 85+). Data were not
available for one Australian state (New South Wales) for
the year 2013.
Patient and public involvement
Patients or the public were not involved in this study.
Statistical analysis of observed incidence
Based on the results of the Interphone study, we analysed
intracranial brain cancer incidence in adults aged 20–59;
2

Table 1 International Classification of Diseases Version 10
histology and topography codes
Histology
 Glioma

9380–9480

 Glioblastoma

9440–9442

 Meningioma

9530–9539

 Other

8010–9371, 9490–9508, 9540–9561

 Unspecified

8000–8004

Glioma grade
 Low (I and II)

9384, 9391, 9393, 9400, 9410, 9411, 9420,
9421, 9424, 9425, 9450

 High (III and IV)

9381, 9392, 9401, 9440–9442, 9451,
9470–9474, 9480

 Unspecified

9380, 9382, 9390, 9423, 9430, 9460

Topography
 Frontal

C711

 Temporal

C712

 Parietal

C713

 Other locations

C700, C701, C709, C710, C714–C717

 Overlapping

C718

 Unspecified

C719

neoplasms of the spinal cord, cranial nerves and other
parts of central nervous system (ICD-10 code C72) were
excluded. Annual age-standardised incidence rates per
100 000 person-years were calculated separately for males,
females and both genders by using WHO’s standard population. Histology was analysed by categorising glioma,
meningioma, other histological types and brain cancers
with unspecified histology based on WHO’s Classification
of tumours of the central nervous system.15 We further
analysed glioma by categorising glioblastoma (which is
the most common brain tumour subtype), glioma grade
(low, high and unspecified) and glioma location (frontal
lobe, temporal lobe, parietal lobe, other locations, overlapping lobes and unspecified). The categories analysed
and their respective ICD-10 codes are shown in table 1.
A large number of tumours had unspecified classifications, particularly for glioma grade and glioma location. We approximated the classification of unspecified
tumours by recalculating the adjusted rates for each year
by adding the unspecified group to the other groups in
proportion to the distribution of specified tumours.
The incidence rates were low compared with the population at risk so the variability in the observed cases was
assumed to follow a Poisson distribution.16 Analyses of
incidence time trends were carried out using Poisson
regression to estimate the annual percentage change
(APC) in the incidence, with corresponding 95% CI over
three time periods: 1982–1992 (representing increased
CT and MRI use), 1993–2002 (representing advances
in MRI) and 2003–2013 (representing substantial and
increasing mobile phone use; more than 65% of the
population).17 Lowess smoothing was used in the graphical representation of the time trends.
Karipidis K, et al. BMJ Open 2018;8:e024489. doi:10.1136/bmjopen-2018-024489
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cancer registries and combined with population exposure
data.8
Since the WHO recommendation, a limited number
of ecological studies have shown that although the prevalence of mobile phone use (usually measured through the
number of mobile phone accounts) has seen a massive
increase, the time trends of brain tumour incidence
have remained fairly stable.9 10 Other studies have shown
increases in certain brain tumour subtypes or specific
anatomical locations.10 11 However, it has been suggested
that the introduction of better diagnostic methods
(CT and MRI) have improved the detection of brain
cancers which leads to increased population incidence.12
Further, a few recent studies, most notably in the USA
and Australia, have shown that predicted incidence rates
based on the associations reported by the Interphone and
Hardell studies for ‘heavy’ mobile phone users are higher
than the observed rates.13 14 Apart from the study by Little
et al,13 previous results have generally failed to show the
incidence trends for different brain tumour histological
and topographical types.13 Further, the simulation of
expected rates in these studies was only performed for
a latency period of 10 years and if there is an association
with mobile phone use the latency could be longer.
In this study, we analysed the incidence trends of brain
tumour for three distinct time periods to ascertain the
influence of improved diagnostic methods and increase
in mobile phone use. The analysis considered different
histological types and subtypes, glioma grades and glioma
anatomical sites. We further compared the observed incidence during the period of substantial mobile phone
use (2003–2013) with predicted incidence for the same
period based on relative risks (RRs) reported by the two
epidemiological studies forming the basis of the IARC
classification.3 4

Open access

Estimated percentage of Australian population using mobile phones.

Mobile phone use data sources
Mobile phone use was estimated using information on
mobile phone accounts and survey data on actual use.
Data on the annual number of mobile phone accounts
from 1987, when mobile telephony first commenced
in Australia, to 2013 were obtained from the national
telecommunications regulator, the Australian Communications and Media Authority (ACMA). The number
of mobile phone accounts per capita for each year was
calculated by dividing the number of accounts by the
total Australian population in that year (obtained from
the Australian Bureau of Statistics), noting that since
2008 the annual number of accounts has been exceeding
the number of people in the population. These data are
not a true indication of mobile phone use as some users
may have had more than one account and other users
no account. A consumer survey conducted by ACMA
reported that approximately 90% of the population used
mobile phones in the years 2009 –2013.18 We estimated
the annual prevalence of mobile phone use (shown in
figure 1) by multiplying the annual number of accounts
per capita by a factor of 0.9.18 It was not possible to stratify
prevalence of use by age or gender; thus, an overall estimate of prevalence is provided equally for all ages across
the 20–59 age range and for both males and females.
Statistical analysis of predicted incidence
With the assumption that mobile phone use is associated with glioma in adults as reported by the Interphone
and Swedish studies, we calculated predicted incidence
rates and time trends by applying various RRs (1.5, 2, 2.5,
Karipidis K, et al. BMJ Open 2018;8:e024489. doi:10.1136/bmjopen-2018-024489

3) and latency periods (1, 5, 10, 15, 20 years) for three
different mobile phone use scenarios:
a. All users—RRs were applied to all mobile phone users.
b. (Heavy users—RRs were applied to heavy mobile
phone users (defined as 19% of mobile phone users by
the Interphone study).
c. Regular users and heavy users—RR of 1.5 applied to
regular users (81% of all users) and RRs of 2, 2.5 and 3
applied to heavy users (19% of all users).
The annual predicted incidence rates were calculated
for the period 1987–2013 using the formula:
Predicted incidence = (P×RR×IB) + ((1−P)×IB)
where P denotes the annual prevalence of mobile
phone use, RR and IB the premobile phone baseline incidence from 1982 to 1987. CIs and statistical significance
of observed and expected incidence rates were calculated using Poisson CIs as described in Ulm.19 Analyses of
predicted incidence time trends were carried out by estimating the APC for the period 2003–2013, representing
the time that mobile phone use increased rapidly.
We used Stata/SE V.15.0 for all analyses. The reporting
of our study conforms to the Strengthening the Reporting
of Observational Studies in Epidemiology statement.20
Results
Observed incidence
There was a total of 16 825 eligible brain cancer cases
aged 20–59 (10 083 males and 6742 females) that were
diagnosed between 1982 and 2013. Of these 15 758
(93.7%) were gliomas, 312 (1.9%) were meningiomas,
3
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Predicted incidence
Assuming a causal association between mobile phone
use and glioma, the predicted incidence trends for both
genders during 2003–2013 by applying various RRs,
latency periods and mobile phone use scenarios are
shown in table 4. The predicted incidence trends showed
an increase for most mobile phone use scenarios and
latency periods that were modelled apart from a 20-year
latency period. There were also no statistically significant increases when applying the model to only heavy
users for RRs less than 3. The highest expected trends
were generally seen for a 10-year latency period, which
was the latency period associated with mobile phones and
brain tumour as reported in the Interphone and Swedish
studies.
The observed and predicted glioma incidence rates for
both genders from 1987 to 2013 are shown in figure 3 for
a 10-year latency and online supplementary figure B for 1,
5, 15 and 20 years latencies. With an RR of 2 for all mobile
phone users and a latency of 10 years, the predicted incidence rate for both genders in 2013 was 7.3 per 100 000
people (95% CI 6.7 to 7.9) compared with the observed
4.5 per 100 000. The predicted rates increase to 8.7 (95%
CI 8.1 to 9.3) and 10.2 (95% CI 9.5 to 10.8) per 100 000
for RRs of 2.5 and 3, respectively. With an RR of 1.5 for
regular users and an RR of 2 for heavy users and a latency
of 10 years the predicted rate was 6.1 per 100 000 (95%
CI 5.6 to 6.6); increasing to 6.4 (95% CI 5.9 to 6.9) and
6.7 (95% CI 6.1 to 7.2) when applying RRs of 2.5 and 3 to
heavy users, respectively. Assuming a latency of 15 years,
the predicted incidence rates in 2013 were also higher
compared with the observed rate. The model did not
show an increasing trend for a latency of 20 years.
Discussion
The results of our study showed that the overall brain
tumour rates in adults aged 20–59 years showed no
increasing or decreasing trend. This is in line with studies
showing stable brain tumour trends in other countries.10–12 Furthermore, the trends in our study were stable
for different histological types, like glioma, which has
been reported in some case–control studies as being associated with mobile phone use.3 4 The all glioma incidence
rates were stable in both the periods before (1982–1992,
1993–2002) and the period after (2003–2013) substantial mobile phone use. For a causal relationship between
mobile phone use and brain cancer, one would expect an
increasing trend in the later period and no trend in the
earlier periods.
There has been limited research showing the time
trends of histological subtypes and particularly glioblastoma, which is the most common and most malignant
brain tumour subtype in adults.5 Philips et al21 reported
that the incidence of glioblastoma more than doubled
in England between 1995 and 2015; however, the
authors did not analyse different periods to investigate the impact of mobile phone use.21 Dobes et al22
Karipidis K, et al. BMJ Open 2018;8:e024489. doi:10.1136/bmjopen-2018-024489
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239 (1.4%) were other histological types and 516 (3.1%)
were tumours of unspecified histology. The most common
brain tumour subtype was glioblastoma (7326, 43.5%). Of
the gliomas, 4699 (29.8%) were low grade, 9300 (59%)
were high grade and 1759 (11.2%) were of unspecified
grade. The most common glioma anatomical location was
the frontal lobe (4422, 28.1%), followed by the temporal
lobe (2952, 18.7%) and parietal lobe (2272, 14.4%).
There were 2372 (15.1%) tumours in other locations,
968 (6.1%) overlapping locations and 2772 (17.6%) with
unspecified location.
The observed incidence rates between 1982 and 2013
are shown in figure 2 for both genders and online supplementary figure A for males and females separately. Further,
the observed incidence trends (given as APC) over the
time periods 1982–1992, 1993–2002 and 2003–2013 are
shown in table 2 for both genders and online supplementary table A for males and females separately. The
overall brain tumour rates remained stable in all three
time periods and the trends were similar for males and
females. Glioblastoma increased during the period that
saw advances in MRI (1993–2002) while it remained stable
during the period of substantial mobile phone use (2003–
2013); this later period also saw a decrease in other glioma
subtypes. The APC for glioblastoma in both genders for
the entire observation period, that is, 1982–2013 (not
shown in table 2) was 1.45 (1.11–1.79). There was a
strong decreasing trend in brain tumours with unspecified histology during the period of increased CT and
MRI use (1982–1992). With the redistribution of unspecified tumours, there were no significant changes to these
histological trends (table 3 for both genders and online
supplementary table B for males and females separately).
Looking at glioma grade in table 2, high-grade gliomas
increased during both periods of improved diagnosis
while low-grade gliomas decreased during the periods
of advances in MRI (1993–2002) and substantial mobile
phone use (2003–2013). There was a strong decreasing
trend in gliomas with unspecified grade during the
period of increased CT and MRI use (1982–1992). The
redistribution of unspecified tumours did not change the
glioma grade trends (table 3).
For glioma location in table 2, there were increasing
trends for all locations and a strong decreasing trend for
unspecified location during the period of increased CT
and MRI use (1982–1992). There were also increases in
the frontal and temporal lobes and a smaller decrease in
unspecified location during the period of advances in MRI
(1993–2002); this period also had a very large decrease in
gliomas with overlapping location. During the period of
substantial mobile use, there were no increases in any of
the locations apart from the frontal lobe and there was a
strong decrease in unspecified location. With the redistribution of a high number of gliomas with unspecified and
overlapping location, there was a much lower increasing
trend only for gliomas in the frontal lobe during all three
periods and a large increase in the parietal lobe during
the first period (table 3).
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Figure 2

Observed incidence rates (smoothed*) in adults (both genders, 20–59 years old) during 1982–2013.
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1982–1992
N
 All

1993–2002
APC

4793

0.1

95% CI

N

APC

(−0.8 to 1)

5270

0.5

2003–2013
95% CI

N

APC

(−0.5 to 1.5)

6762

−0.8

95% CI
(−1.6 to 0)

Histology
 Glioma

4347

1.1

(0.2 to 2.1)

4990

0.4

(−0.6 to 1.4)

6421

−0.6

 Glioblastoma

1638

1.4

(−0.1 to 2.9)

2397

2.3

(0.8 to 3.7)

3291

0.8

 Other glioma

2709

1

(−0.2 to 2.2)

2593

−1.2

(−2.6 to 0.1)

3130

−1.8

(−2.9 to 0.7)

 Meningioma

82

−0.4

(−6.9 to 6.6)

110

2.4

(−4.2 to 9.4)

120

−4.4

(−10.1 to 1.7)

 Other
 Unspecified

(−1.4 to 0.2)
(−0.4 to 2)

79

−7.3

(−13.6 to 0.6)

66

−1.5

(−9.5 to 7.2)

94

−5.3

(−11.3 to 1)

285

−13.4

(−16.6 to 10)

104

4.6

(−2.3 to 12)

127

−4.8

(−10.3 to 0.9)

Glioma grade
 Low

1817

1.1

(−0.4 to 2.6)

1418

−3.8

(−5.5 to 2)

1464

−3.1

(−4.7 to 1.5)

 High

1938

3.8

(2.3 to 5.2)

3151

2.1

(0.9 to 3.4)

4211

−0.1

(−1.1 to 1)

592

−6.9

(−9.2 to 4.5)

421

2.2

(−1.2 to 5.7)

746

2

 Unspecified

(−0.4 to 4.5)

Glioma location
 Frontal

933

7.8

(5.6 to 10.1)

1345

3.7

(1.8 to 5.7)

2144

3

(1.6 to 4.5)

 Temporal

599

7.3

(4.6 to 10.1)

982

2.8

(0.6 to 5.2)

1371

0.5

(−1.3 to 2.3)

 Parietal

655

6.4

(3.9 to 9.1)

801

−1.3

(−3.7 to 1.1)

816

−0.4

(−2.7 to 2)

 Other locations

605

5.1

(2.5 to 7.8)

778

0.5

(−1.9 to 3)

989

−1.7

(−3.8 to 0.3)

 Overlapping

298

3.5

(−0.1 to 7.3)

296

−8.8

(−12.5 to 5)

374

−2.3

(−5.6 to 1.1)

 Unspecified

1257

−10.8

(−12.4 to 9.2)

788

−2.9

(−5.2 to 0.4)

727

−10.5

(−12.7 to 8.2)

APC, annual percentage change.

reported an increasing trend in glioblastoma incidence
in Australia between 2000 and 2008 in people aged 65
years or older; noting that the cases were ascertained

directly from neurological centres.22 Our study used all
the national incident brain cancer registrations available through Australia’s high-quality state and territory

Table 3 Observed age-standardised brain tumour incidence trends in adults (both genders, 20–59 years old) after
redistribution of unclassified tumours
1982–1992
N

APC

1993–2002
95% CI

N

APC

2003–2013
95% CI

N

APC

95% CI

All
Histology

4793

0.1

(−0.8 to 1)

5270

0.5

(−0.5 to 1.5)

6762

−0.8

(−1.6 to 0)

 Glioma

4623

0.2

(−0.7 to 1.2)

5094

0.5

(−0.5 to 1.5)

6547

−0.7

(−1.5 to 0.1)

 Glioblastoma

1746

0.4

(−1.1 to 1.9)

2445

2.4

(0.9 to 3.8)

3353

0.7

(−0.5 to 1.9)

 Other glioma

2886

0.1

(−1 to 1.2)

2649

−1.1

(−2.5 to 0.2)

3195

−1.9

(−3 to 0.8)

 Meningioma

84

−1.6

(−7.9 to 5.2)

110

2.4

(−4.2 to 9.4)

120

−4.4

(−10.1 to 1.7)

 Other

82

−8.6

(−14.7 to 2)

66

−1.5

(−9.5 to 7.2)

94

−5.3

(−11.3 to 1)

 Low

2107

−0.2

(−1.5 to 1.2)

1548

−3.6

(−5.3 to 1.9)

1659

−2.8

(−4.3 to 1.3)

 High

2240

2.4

(1.1 to 3.7)

3442

2.3

(1.1 to 3.5)

4762

0.2

(−0.7 to 1.2)

1447

1.8

(0.2 to 3.5)

1719

2.3

(0.6 to 4)

2580

1.6

(0.3 to 2.9)

 Temporal

929

1.8

(−0.2 to 3.9)

1252

1.5

(−0.5 to 3.5)

1656

−1.2

(−2.8 to 0.4)

 Parietal
 Other locations

803
948

3.4
−0.5

(1.2 to 5.7)
(−2.5 to 1.5)

894
996

–2
−0.8

(−4.2 to 0.3)
(−3 to 1.4)

880
1198

−1.1
−3.3

(−3.3 to 1.1)
(−5.1 to 1.4)

Glioma grade

Glioma topography
 Frontal

APC, annual percentage change.

6

Karipidis K, et al. BMJ Open 2018;8:e024489. doi:10.1136/bmjopen-2018-024489

BMJ Open: first published as 10.1136/bmjopen-2018-024489 on 9 December 2018. Downloaded from http://bmjopen.bmj.com/ on 2 January 2019 by guest. Protected by copyright.

Table 2 Observed age-standardised brain tumour incidence trends in adults (both genders, 20–59 years old) during increased
CT and MRI use (1982–1992), advances in MRI use (1993–2002) and substantial mobile phone use (2003–2013)
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APC, annual percentage change; RR, relative risk.
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(3.8 to 5.2)

95% CI

(0.7 to 2.4)
(−0.7 to 1)

(2.4 to 4)

(0.5 to 1.9)
(2.4 to 3.9)

RR=1.5 (R), 2 (H)

0.5
0.1

0.5

1.2

0.5

0.3

2.5

4.9

1.6
4.5

APC

RR=2

1
5

(−0.6 to 1.1)
(−0.8 to 0.9)

(−0.6 to 1.1)

(−0.2 to 1.5)

0.6

5

(−0.7 to 1)

10

0.2
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(0.5 to 2.2)
(−0.6 to 1.1)

1.3
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(1.9 to 3.6)

(0.3 to 1.8)
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0.3
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1

1.1
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95% CI

2.0
0.2
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1.0
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8.2

2.3
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Regular users
and high users

RR=1.5

APC

1
5

Latency

Predicted glioma incidence trends for both genders (20–59 years) during 2003–2013

High users

All users

Scenario

Table 4

Open access
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Open access

population-based cancer registration system. Registration
is mandatory and histological verification rates exceed
85%.14 In our study, which focused on the age group
most likely to be affected by mobile phone use, there
was an increasing trend for glioblastoma when looking
at the entire observation period (1982–20130). However,
when looking at different time periods, there was no
increase in the glioblastoma rates during the period of
substantial mobile phone use but there was an increase
in the glioblastoma rates in the earlier periods: 1982–
1992 (non-statistically significant increase), which saw
increased use of CT and MRI, and 1993–2002 (statistically
significant increase) which saw further advances in MRI.
8

Technological developments in MRI during 1993–2002,
including diffusion and perfusion imaging, improved
significantly the discrimination of brain tumour types
and subtypes.17 23 Other factors, such as improved access
to care and an increase in the number of specialists, may
also have played a role in the increase.9 Earlier studies
investigating trends in brain tumour subtypes including
glioblastoma have commented that increases in certain
subtypes are accompanied by decreases in other subtypes
while overall brain tumour incidence has remained
stable.24 25 These studies suggest improvements in diagnostic technology as the reason for increasing trends in
certain brain tumour subtypes.24 25
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Figure 3 Observed (smoothed*) and predicted (10-year latency) incidence rates in adults (both genders, 20–59 years old)
during 1982–2013. RR, relative risk.
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latency periods up to 20 years. Our model found that the
predicted incidence rates were higher than the observed
rates for a latency period up to 15 years. A longer observation period is required in order to model longer latency
periods.
The present study has some limitations. The accuracy
of the Australian cancer registration system in the early
periods when it began in the 80s is unknown for all the
states and territories. In Northern Territory mandatory
notification of cancer cases by pathology laboratories was
introduced in 1991. Case ascertainment was found to be
approximately 40% incomplete for the period 1981–1986
and approximately 10% incomplete for the period 1987–
1990. However, the Northern Territory makes up a very
small proportion of Australia’s population (~1%).30 All
Australian state and territory registries conform to the
IARC’s criteria for population-based cancer registration,
are ‘A’ rated and have their data published in the ‘Cancer
Incidence in Five Continents’ series.14 31
We estimated mobile phone use using information
on mobile phone accounts, and this may not be a true
indicator of actual use as some people may have multiple
accounts and others may use a phone without having
an account. We mitigated this by also using data from a
consumer survey conducted by the national telecommunications regulator on the proportion of the population
using mobile phones. Information from the survey was
only available from the years 2009 to 2013 and this was
applied to data on the annual number of mobile phone
accounts from 1987. However, mobile phone use patterns
have likely changed from 1987 to 2009. Further, the exposure metric is unclear when investigating whether mobile
phone use is implicated in brain cancer risk. Prevalence
of phone use is a de facto measure for the amount of RF
energy a person is receiving when using a mobile phone,
and changes in technology and patterns of individual
use were not taken into account in this investigation. For
example, advances in mobile telephony have resulted
in greatly reduced output power of the phones and the
evolving use of mobile phones has resulted in less actual
calling time with the phone against the head.
We estimated the prevalence of mobile phone use
equally across the 20–59 age range and both males and
females. The use of subscription data in early years is
likely to underestimate prevalence of use in males and
overestimate it in females given that users in early years
were middle-aged working men on company mobile
phone subscriptions.14 In later years mobile phone use
became equal between the two genders.32
For information on the proportion of regular and heavy
mobile phone users, we used data from the Interphone
study, which also included data from Australia. Mobile
phone use in the Interphone study was self-reported,
relying on participants’ recall of past phone use.3 Sensitivity analyses on the Interphone methodology reported
that for short term recall (up to a year) there was underestimation of phone use by regular users and overestimation by heavy users.33 For longer recall (3–5 years), there
9
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The results on histology are consistent with the results by
grade, as high-grade glioma is approximately equivalent
to glioblastoma. During the period of advances in MRI,
there was an increase for high-grade lesions and a decrease
for low-grade, both which levelled off during the period
of substantial mobile phone use. These results are consistent with incidence trends reported by Barchana et al26 for
low-grade and high-grade gliomas in Israel between 1980
and 2009.26 Furthermore, there was a strong decrease for
unspecified histology and for unspecified grade during
the first period, and this is likely due to improvements
in diagnosis using CT and histopathological classification.27 There have also been shifts in classifying subtypes
and grade in updated editions of WHO classification; for
example, WHO 2000 classification induced a shift from
anaplastic astrocytoma to glioblastoma.
The results on anatomical location showed that there
was an increase in gliomas located in the temporal and
parietal lobes prior to the period of substantial mobile
phone use, but not during it. There were increases for
gliomas located in the frontal lobe both before and during
increased mobile phone use, however, the temporal and
parietal lobes are more highly exposed to RF radiation
than other brain sites when using mobile phones. Cardis
et al1 reported that depending on the type of mobile
phone and the manner in which it is used, the RF energy
absorption is at least several times higher in the temporal
lobe than in the frontal lobe.1 In our data there was a
large number of gliomas with unspecified or overlapping
location. Reclassification of these did reduce the trends
for the temporal lobe during the periods before substantial mobile phone use, and for the frontal lobe during all
the periods.
In our study, we also compared the observed incidence
with a modelled predicted incidence assuming a causal
association between mobile phone use and glioma as
reported in the Interphone and Hardell studies. The
results suggest that, if the effects of mobile phones on
glioma risk are real, then the incidence rates would be
far higher than those observed. We modelled predicted
incidence rates for a variety of latency periods up to 20
years whereas previous studies only included latencies up
to 10 years.12 13 Previous studies by Little et al13 and more
recently by Chapman et al14 have also shown that when
modelling the RRs from the Interphone and Hardell
studies and assuming a latency of 10 years, the predicted
incidence rates are much higher.13 14 The exact causes of
brain cancer are unknown and so is the latency period for
the disease. Ionising radiation has been shown to induce
brain cancer by causing DNA damage with a latency
period of about 5 or more years.28 RF exposure is non-ionising radiation which does not cause direct DNA damage
and it has been argued that a possible effect would have
a latency shorter than 5 years.13 However, it has also been
argued that the latency for an increased risk of brain
cancer could be both short and long, indicating tumour
initiation and promotion, respectively.29 In our study,
we modelled predicted incidence rates for a variety of
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was an underestimation of number of calls and an overestimation on the duration of calls for all users.34 Based
on these findings, it is likely that the proportion of heavy
users in our study is overestimated. Further, the real
patterns of mobile phone use may be more complex than
the scenarios we modelled.
Finally this is an ecological observational study, not
based on individual data, thus, it is not possible to
account for confounding factors. This study design is
appropriate to define global trends. The results of our
study are prone to the ecological fallacy and small risks in
subgroups in the population may not have been detected.
Further, the stable trend in brain tumour incidence could
have concealed a true increasing risk related to mobile
phone use which appeared flat due to declines in other
risk factors.
In conclusion, we found no evidence that mobile
phone use increased any brain tumour histological types
or subtypes. There was an increase in the incidence of
glioblastoma prior to the rapid increase in mobile phone
use which was most likely due to improved diagnosis from
MRI. Furthermore, there was no increase in gliomas of
the temporal lobe, which is the most exposed location,
during the period of substantial mobile phone use. The
increase in gliomas of the temporal lobe and decrease
in gliomas of unspecified location during the periods
prior to substantial mobile phone use are in line with the
theory of improved diagnosis from CT and MRI. Further,
the predicted rates were higher than the observed rates
for latency periods up to 15 years. These results do not
support an association between mobile phone use and
brain tumour, although the possibility of a small risk or a
latency period of more than 15 years cannot be excluded.
Future research should continue to investigate trends in
brain tumour histological types, grading and anatomical location for a possible increase with a longer latency
period.
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